Epilepsy

Apr 21, 2026

Novo Nordisk’s Etavopivat Meets Phase 3 Endpoints in Sickle Cell Disease Novo Nordisk announced topline findings from HIBISCUS, a pivotal Phase 3 study evaluating once-daily oral etavopivat in adults and adolescents living with Sickle Cell Disease. The trial met both co-primary endpoints, with etavopivat showing...

Feb 09, 2026

Summary Drug-resistant epilepsy affects 20-40% of epilepsy patients in the US, rising to 30-40% in adults versus 7-20% in children, with similar rates (over 25%) in Europe; about one-quarter of newly diagnosed cases progress to DRE. Vagus Nerve Stimulation (VNS Therapy by LivaNova) is FDA-approved for drug-r...

Feb 09, 2026

Epilepsy is a chronic neurological disorder that affects millions of people across the globe and is characterized by recurrent, unprovoked seizures. Despite major advances in neuroscience and pharmacology, epilepsy remains surrounded by social stigma, misconceptions, and unanswered questions. In the 7MM, the total ...

Dec 03, 2025

Epilepsy affects nearly 50 million people globally, making it one of the most common neurological disorders, with about 80% of cases occurring in low- and middle-income countries where diagnostic and treatment resources are limited. Yet with timely and appropriate care, up to 70% of individuals with epilepsy can be...

Oct 28, 2025

Wireless brain sensors are emerging as a transformative technology in neuroscience and healthcare, offering a new level of precision, comfort, and real-time monitoring for patients with neurological conditions. Unlike traditional wired sensors that limit mobility and can cause discomfort, wireless brain sensors use...

Aug 09, 2025

Epilepsy is a chronic neurological condition characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. Affecting over 50 million people globally, it remains one of the most prevalent neurological disorders. Understanding the various types of seizures, including generalized...

May 01, 2024

The healthcare market has witnessed a remarkable transformation in recent years, largely driven by rapid advancements in technology and innovation. Among the most notable developments is the evolution of wearable medical devices, which have transcended their traditional roles to become indispensable tools in the mo...

Jun 06, 2022

Epidiolex (Jazz Pharma) and Fintepla (Zogenix - Acquired by UCB) are locking horns in the rare developmental and epileptic encephalopathies (DEE) market with Epidiolex currently leading in terms of sale. Epidiolex has clocked over USD 650 million in sales and on the other hand Fintepla is far behind at just USD 74....

May 19, 2022

Check-Cap Initiated the US Pivotal Trial for C-Scan® On May 11, 2022, Check-Cap Ltd., a clinical-stage diagnostic company initiated the US pivotal trial for C-Scan® at Mayo Clinic in Rochester Minnesota. C-Scan is the first and only patient-friendly, preparation-free screening test to detect polyps before they m...

Mar 29, 2022

Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B and B, has been approved for the treatment of children and adults with non-CNS manifestations of Acid Sphingomyelinase D...